NAROPIN® is indicated for the production of local or regional
anesthesia for surgery and for acute pain management.

Important Safety Information
Using NAROPIN beyond recommended doses to increase motor block or duration of sensory block may negate its favorable cardiovascular advantages, in the event that an inadvertent intravascular injection occurs.
NAROPIN may be associated with adverse reactions which are characteristic of those associated with other amide-type local anesthetics.1 In clinical trials, side effects were mild and transient and may reflect the procedures, patient health status, and/or other medications used. Adverse events reported at a rate of ≥5%: hypotension, nausea, vomiting, bradycardia, fever, pain, postoperative complications, anemia, paresthesia, headache, pruritus, and back pain.

New Safety Information
There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. NAROPIN is not approved for this use.

Please see Full Prescribing Information at

1. NAROPIN® Prescribing Information. Data on file.

NAROPIN® and logo are registered trademarks of Fresenius Kabi USA, LLC.
©2012, Fresenius Kabi USA, LLC. All Rights Reserved.